Date of Award
1-1-2018
Document Type
Open Access Thesis
Degree Name
Medical Doctor (MD)
Department
Medicine
First Advisor
Robert A. Cowles
Abstract
Parenterally-administered selective serotonin reuptake inhibitors (SSRI), such as citalopram, increase intestinal mucosal absorptive surface by day 7 of treatment. We hypothesized that enteral citalopram would also induce intestinal mucosal growth, thus allowing for therapy with an oral agent. In the study’s first phase, C57BL/6 mice received peanut butter (PB) pellets containing 10, 50, or 100 mg/kg/day citalopram for 7 days; or 25 mg/kg/day citalopram for 14 or 21 days; or plain PB pellets for 7, 14, or 21 days. In the second phase, C57BL/6 mice received 0, 10, 25, or 50 mg/kg/day citalopram in drinking water for 2, 3, 6, or 8 weeks, or for 6 weeks followed by 2 weeks of drug withdrawal. Two-centimeter ileal segments were harvested and prepared for microscopic assessment of villus height (VH), crypt depth (CD), villus width (VW), and crypt width (CW). Mucosal surface area (MSA) was calculated and data were compared using Student’s t-test. Enteral citalopram given for 14 days in PB pellets resulted in an increased VH (p
Recommended Citation
Zhang, Lucy, "Orally-Dosed Citalopram Stimulates Small Intestinal Mucosal Growth" (2018). Yale Medicine Thesis Digital Library. 3466.
https://elischolar.library.yale.edu/ymtdl/3466
